Howie and Harlan are joined by Melissa Davis, a Yale radiologist and a graduate of Yale SOM’s MBA for Executives program, to discuss the ‘whoa’ moments and the weaknesses she has encountered using artificial intelligence to help interpret scans. Harlan reflects on the slow progress toward a healthcare system that rewards value rather than volume; Howie reports on new treatments for Alzheimer’s disease. 

Links:

“Robert F. Kennedy Jr. suggests covid was designed to spare Jews, Chinese people”

“The Medicare Physician Fee Schedule and Unethical Behavior”

“Vinod Khosla: Machines will replace 80 percent of doctors”

“Affirmative action ruling raises concerns over impact on medical school diversity”

Yale School of Management: MBA for Executives

Sepsis DX, co-founded by Melissa Davis

“Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial”

“Editorial: Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease”

Learn more about the MBA for Executives program at Yale SOM.

Email Howie and Harlan comments or questions.